Save this page
Save this page

My Saved Pages

  • Saved page.

My Saved Courses

  • Saved page.
Reset

Recently visited

  • Saved page.

Dr Christine Dufès

Senior Lecturer

Strathclyde Institute of Pharmacy and Biomedical Sciences

Personal statement

Dr Christine Dufès is a Senior Lecturer (Associate Professor) at the Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS). She teaches on the Master of Pharmacy and on various MSc / MRes postgraduate degrees.

Christine obtained a Doctorate in Pharmacy (with Distinction and congratulations of the Jury, 1997) and a PhD (with a European Label, Distinction and congratulations of the Jury, 2002) from the University of Poitiers (France). After four years as a post-doctoral researcher at the Cancer Research UK Beatson Laboratories in Glasgow, she was appointed as a Lecturer at SIPBS in 2006, obtained fellowship of the Higher Education Academy in 2007 and became a Senior Lecturer in 2012.

Christine has been awarded the Biochemical Journal Young Investigator Award (2009) and the Tom Gibson Memorial Award (2012) for her research, in addition to the Best Overall Strathclyde Teaching Excellence Award (2013) for her teaching. She sits on the editorial boards for 18 journals.

Her research interests are:

  • Design and development of novel tumour-targeted anti-cancer nanomedicines.
  • Design and development of novel nanomedicines able to reach the brain after intravenous administration, with the ultimate aim to facilitate drug and gene delivery to brain tumours and neurodegenerative disorders.

Her research highlights include:

  • Tumour regression after intravenous administration of a tumour-targeted dendriplex  encoding TNFα (complete disappearance of 90% of the tumours)
  • Tumour regression after intravenous administration of tumour-targeted vesicles entrapping tocotrienol (complete disappearance of 40% of the tumours) (doctoral work of Dr Ju Yen Fu)
  • Tumour regression after intravenous administration of a tumour-targeted dendriplex encoding p73 (complete disappearance of 10% of the tumours)
  • Tumour regression after intravenous administration of the green tea extract epigallocatechin gallate encapsulated in tumour-targeted vesicles (complete disappearance of 40% of the tumours)
  • Regression of prostate tumours after intravenous administration of tumour-targeted dendriplexes encoding TNFα, TRAIL and IL-12 (complete disappearance of up to 60% of PC-3 tumours and up to 50% of DU145 tumours) (doctoral work of Dr Majed Al Robaian).
  • Increase of gene expression in tumours by surface modification of polyethylenimine and polypropylenimine dendrimer with the amino acids arginine, lysine and leucine (doctoral work of Dr Hibah Aldawsari)
  • Increase of gene expression in the brain following intravenous injection of transferrin-bearing dendriplex (at least twice higher than that of the unmodified dendriplex), while decreasing the non-specific gene expression in the lung. Gene expression was at least 3-fold higher in the brain than in any tested peripheral organs (doctoral work of Dr Sukrut Somani).

Podcast about recent research results: http://www.youtube.com/embed/JhbIoXsAM7M 

Website: http://www.dufeslab.com/

 

Prizes and awards

Award of the "Best Overall" Strathclyde Teaching Excellence award 2013
Recipient
5/2013
Nominations and short-listings at the Strathclyde Teaching Excellence Awards
Recipient
2013
Tom Gibson Memorial Award 2012
Recipient
6/2012
Biochemical Journal Young Investigator Award
Recipient
4/2009
First Prize Award of the 9th Annual Symposium of the United Kingdom and Ireland Controlled Release Society
Recipient
10/1/2003
French Bourse d'Excellence Lavoisier
Recipient
1/2002

more prizes and awards

Publications

Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol
Karim Reatul, Somani Sukrut, Al Robaian Majed, Mullin Margaret, Amor Rumelo, McConnell Gail, Dufès Christine
Journal of Controlled Release Vol 246, pp. 79-87, (2017)
http://dx.doi.org/10.1016/j.jconrel.2016.12.014
Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex
Somani Sukrut, Robb Gillian, Pickard Benjamin S., Dufes Christine
Journal of Controlled Release Vol 217, pp. 235-242, (2015)
http://dx.doi.org/10.1016/j.jconrel.2015.09.003
Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes
Lim Li Ying, Koh Pei Yin, Somani Sukrut, Al Robaian Majed, Karim Reatul, Yean Yi Lyn, Mitchell Jennifer, Tate Rothwelle J., Edrada-Ebel RuAngelie, Blatchford David R., Mullin Margaret, Dufès Christine
Nanomedicine: Nanotechnology, Biology and Medicine Vol 11, pp. 1445-1454, (2015)
http://dx.doi.org/10.1016/j.nano.2015.04.006
Transferrin-bearing dendrimers for cancer therapy : an update
Somani Sukrut, Dufes Christine
Nanomedicine Vol 10, pp. 2125-2127, (2015)
http://dx.doi.org/10.2217/nnm.15.93
Anti-cancer efficacy of intravenously administered tumor-targeted vesicles entrapping tocotrienol
Fu Ju Yen, Dufès Christine
Pharmaceutical Nanotechnology Vol 2, pp. 172-181, (2015)
http://dx.doi.org/10.2174/2211738503666150119231232
Applications of dendrimers for brain delivery and cancer therapy
Somani Sukrut, Dufès Christine
Nanomedicine Vol 9, pp. 2403-2414 , (2014)
http://dx.doi.org/10.2217/nnm.14.130

more publications

Teaching

Christine Dufès teaches on the Master of Pharmacy and on various MSc / MRes postgraduate degrees. 

  • TEACHING COORDINATION:

- Year Coordinator for Year 2 MPharm

- Class coordinator for Medicines manufacture and Quality Control 2 (MP415)

- Class coordinator for Advanced Drug Discovery class (MP506)

- Class coordinator for the MRes Advanced topics in pharmaceutical materials and formulation (MP958)

- Class coordinator for the MRes Advanced topics in drug discovery (MP978)

 

  • UNDERGRADUATE TEACHING (MPharm)

- Being a Pharmacist (MP220)

- Normal function of the gastrointestinal system (MP221)

- Normal function of the nervous and endocrine systems (MP223)

- Management of Infection and Infectious Diseases (MP321)

- Medicines Manufacture and Quality Control 2  (MP415, MC413)

- Advanced drug discovery (MP506)

- Clinical pharmacology and prescribing (MP509)

  

  • POSTGRADUATE TEACHING

- Bioanalysis, biotechnology and quality management (MP919)

- Advanced techniques in pharmaceutical materials and formulation (MP948)

- Advanced topics in pharmaceutical materials and formulation (MP958) 

 

Research interests

  • Design and development of novel tumour-targeted anti-cancer nanomedicines.
  • Design and development of novel nanomedicines able to reach the brain after intravenous administration, with the ultimate aim to facilitate drug and gene delivery to brain tumours and neurodegenerative disorders.

Professional activities

21st World Congress on Clinical Nutrition (Budapest, Hungary)
Invited speaker
6/10/2017
Pharmaceutical Research (Journal)
Peer reviewer
10/2017
Biotechnology and Bioengineering (Journal)
Peer reviewer
10/2017
External examiner for 1 PhD candidate
Examiner
10/2017
British Society of Nanomedicine conference
Speaker
10/8/2017
4th World Congress and Expo on Nanotechnology and Materials Science (Barcelona, Spain)
Invited speaker
4/2017

more professional activities

Projects

Development of novel gene delivery systems for brain targeting by intravenous administration
Dufes, Christine (Principal Investigator) Pickard, Benjamin (Co-investigator)
Period 01-May-2016 - 30-Apr-2019
Development of targeted nanomedicines to treat prostate cancer
Dufes, Christine (Principal Investigator)
Period 01-Jun-2016 - 31-May-2019
The Role Of S1P4 And SK1 In Triple Negative Breast Cancer
Pyne, Nigel (Principal Investigator) Dufes, Christine (Co-investigator) Pyne, Susan (Co-investigator)
Period 06-Feb-2013 - 05-Feb-2014
Development of tumour-targeted gene delivery systems for intravenous cancer therapy
Dufes, Christine (Principal Investigator)
"Cancer kills more people in the UK than any other disease: one cancer sufferer dies every 15 minutes, which adds up to over 35 000 people a year. The possibility of using genes as medicines to treat cancer is currently limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. On the basis that iron is essential for tumour cell growth and can be effectively carried to tumours by using specific iron-carrier receptors present in abundance on the surface of cancer cells, we demonstrated that the use of iron-carriers linked to a highly promising gene delivery system resulted in gene expression mainly in the tumours after intravenous administration. This led to a rapid and sustained tumour regression over one month, with disappearance of 90% of the tested tumours and regression of the remaining ones in a laboratory model. Building on the promising results already obtained, the proposed project aims to develop new systems by modifying the iron-carrier, and to evaluate their anti-cancer efficacy on cancer cells in vitro and in vivo after intravenous administration. This innovative research would potentially have a major impact on healthcare, as there is currently no gene medicine commercially available for the intravenous treatment of cancer."
Period 01-Jun-2012 - 31-May-2015
Evaluation and Optimization of a novel non-viral gene delivery system for brain targeting by intravenous administration
Dufes, Christine (Principal Investigator)
Evaluation of a novel non-viral gene delivery system for brain targeting by intravenous administration
Period 01-Mar-2012 - 31-Jul-2015
Evaluation of the therapeutic efficacy of a novel tumour-targeting gene delivery system on prostate cancers
Dufes, Christine (Principal Investigator)
Period 01-May-2010 - 30-Apr-2012

more projects

Address

Strathclyde Institute of Pharmacy and Biomedical Sciences
John Arbuthnott Building Robertson Wing

Location Map

View University of Strathclyde in a larger map